Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.\* 無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 2359)

## COMPLETION OF THE REPURCHASE AND CANCELLATION OF PART OF THE RESTRICTED A SHARES GRANTED UNDER THE 2018 A SHARE INCENTIVE PLAN AND THE 2019 A SHARE INCENTIVE PLAN

References are made to the announcements of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the "**Company**") dated August 26, 2021 in relation to, among other things, the repurchase and cancellation of part of the Restricted A Shares granted under the 2018 A Share Incentive Plan and the 2019 A Share Incentive Plan (the "**Announcement**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

On August 31, 2021, the repurchase and cancellation of the Repurchased Restricted A Shares have been completed. The issued share capital of the Company has been reduced from 2,953,065,829 Shares (being the issued share capital of the Company as at August 30, 2021 which comprises 2,564,059,611 A Shares and 389,006,218 H Shares) to 2,952,374,830 Shares (being the issued share capital of the Company as at the date of this announcement which takes into account only the repurchase and cancellation of the Repurchased Restricted A Shares, and comprises 2,563,368,612 A Shares and 389,006,218 H Shares).

By order of the Board WuXi AppTec Co., Ltd.\* Dr. Ge Li Chairman

Hong Kong, August 31, 2021

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

\* For identification purposes only